News and Media

Press Release

iCo Therapeutics Named One of Canada’s Top Investment Prospects

November 8, 2005

Vancouver, CANADA – iCo Therapeutics has been selected as a finalist in Canada’s Top 10 Life Sciences Companies Competition for 2005/2006. In being named one of Canada’s Top 10, the Council recognizes iCo Therapeutics’ future investment potential and provides iCo the opportunity to present to the North American investment community at the prestigious BioNorth 2005, a premier conference for life sciences companies.

“It is indeed an honour to be selected as one of Canada’s Top 10 by the Ottawa Life Sciences Council,” said iCo Therapeutics Chief Executive Officer Andrew Rae. “I would like to congratulate all of the other finalists. This not only acknowledges iCo’s potential but also the promise and vitality of the greater Canadian biopharmaceutical and scientific community.”

In addition to presenting at BioNorth 2005, iCo Therapeutics and the other finalists will have an opportunity to present their business plans to an audience of investors, venture capitalists and potential strategic alliance partners at investment forums in New York, Boston and San Francisco. Since its inception, Canada’s Top 10 alumni have raised over $480 million collectively in venture capital funding after being named finalists.

“This represents a singular opportunity to secure the means to help bring us even closer to achieving our business goals,” added Rae.

Jurors for this year’s awards include representatives from eleven of the top venture capital companies in Canada and the U.S. For a list of jurors and their profiles, visit

About iCo Therapeutics, Inc.

iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology company focused on developing pre-existing drugs for a range of new conditions affecting isolated biological environments – areas such as the eye, spinal cord, or joints – where locally-administered application of these therapies would have minimal systemic distribution and fewer safety issues.

For more information, visit the company website at:

Business Development Contact:
Dr. John Clement, CTO

Finance/Investor Contact:
Mr. John Meekison, CFO